Key result
In older patients with moderate to severe secondary mitral regurgitation, frailty significantly increased the risk of heart failure hospitalization and all-cause mortality at 1 year (HR 3.70).
Why the study?
Identifying responders to interventions among patients with functional mitral regurgitation is challenging, and frailty may serve as a multidimensional marker of resilience to stressors.
Does frailty predict hospitalization for heart failure and all-cause mortality in older patients with moderate to severe secondary mitral regurgitation?
Cohort (n=239)
No
Does frailty predict hospitalization for heart failure and all-cause mortality in older patients with moderate to severe secondary mitral regurgitation?
Hazard Ratio: 3.7 (95% CI 2.12–6.47)
Absolute Event Rate: 43% vs 14%
p-value: p=<0.001
Frailty, as assessed by the Clinical Frailty Scale, is a strong independent predictor of 1-year mortality and heart failure readmission in older patients with secondary mitral regurgitation, outperforming the EuroSCORE II.
Frailty assessment may refine prognostication in secondary MR; leaves open its utility for intervention selection.
INTRODUCTION: Selection in patients with functional mitral regurgitation (MR) to identify responders to interventions is challenging. In these patients, frailty might be used as a multidimensional parameter to summarize the resilience to stressors. Our objective was to evaluate frailty as a predictor of outcome in patients with moderate to severe secondary MR. METHODS: We conducted a single-center retrospective observational cohort study and included 239 patients with moderate to severe secondary MR aged 65 years or older between 2014 and 2020. Echocardiography was performed at baseline; frailty was evaluated using the clinical frailty scale (CFS). The combined primary endpoint was hospitalization for heart failure and all-cause mortality. RESULTS: A total of 53% (127) of all patients were classified as CFS 4 (living with mild frailty) or higher. Frail patients had a higher risk for the combined endpoint (hazard ratio, HR 3.70, 95% confidence interval, CI 2.12-6.47; p < 0.001), 1‑year mortality (HR 5.94, 95% CI 1.76-20.08; p < 0.001) even after adjustment for EuroSCORE2. The CFS was predictive for the combined endpoint (AUC 0.69, 95% CI 0.62-0.75) and outperformed EuroSCORE2 (AUC 0.54, 95% CI 0.46-0.62; p = 0.01). In sensitivity analyses, we found that frailty was associated with adverse outcomes at least in trend in all subgroups. CONCLUSION: For older, medically treated patients with moderate to severe secondary mitral regurgitation, frailty is an independent predictor for the occurrence of death and heart failure-related readmission within 1 year and outperformed the EuroSCORE2. Frailty should be assessed routinely in patients with heart failure to guide clinical decision making for mitral valve interventions or conservative treatment.
No takes yet. Share an insight, caveat, or question.
Uzel et al. (2023) conducted a cohort in Moderate to severe secondary mitral regurgitation (n=239). Frailty (Clinical Frailty Scale ≥ 4) vs. No frailty (Clinical Frailty Scale 1-3) was evaluated on Combined endpoint of hospitalization for heart failure and all-cause mortality at 1 year (HR 3.70, 95% CI 2.12-6.47, p=<0.001). In older patients with moderate to severe secondary mitral regurgitation, frailty significantly increased the risk of heart failure hospitalization and all-cause mortality at 1 year (HR 3.70).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: